Pulnovo Medical has received IDE approvals for the PADN system, enabling crucial clinical trials for pulmonary hypertension with full CMS coverage.

Recent research highlights how Stanniocalcin-1 could be crucial in treating idiopathic pulmonary arterial hypertension by inhibiting vascular remodeling.

Pulnovo Medical unveiled significant results from the PADN-HF-PH study, demonstrating major advancements in treating pulmonary hypertension at ESC 2026.

Pulnovo Medical has successfully enrolled its first two patients in the PULSE-LHD clinical trial in the U.S., aiming to treat pulmonary hypertension linked to left heart disease. This marks a significant advancement in the field.

This article explores the dynamics of the pulmonary arterial hypertension market, emphasizing its projected growth, emerging therapies, and market opportunities between 2022 and 2036.

AllRock Bio has commenced its Phase 2a ROCSTAR trial, administering ROC-101 to patients with pulmonary hypertension to assess safety and efficacy combined with standard therapies.

In celebration of Rare Disease Day, phaware global association introduces the Heart Works app designed to support the pulmonary hypertension community through connection and education.

Cereno Scientific is broadening its clinical focus for CS014 to target pulmonary hypertension linked to interstitial lung disease, addressing significant unmet medical needs.

Cereno Scientific celebrates FDA clearance to commence a Phase IIb trial for CS1, a potential treatment for pulmonary arterial hypertension. The trial aims to improve patient outcomes.

The American Lung Association has launched a free program to educate families about pulmonary arterial hypertension, aiming to improve diagnosis and management.

AllRock Bio Inc. has successfully raised $50 million to advance ROC-101, its lead clinical candidate aimed at treating pulmonary hypertension and interstitial lung disease.

Synhale Therapeutics has acquired Telaglenastat, a key move to enhance the company's clinical programs for pulmonary hypertension, targeting unmet patient needs.

Eko Health has published a pivotal research study showcasing AI's potential in the early detection of pulmonary hypertension, marking a significant advancement in cardiopulmonary health.